The impact of acute-phase reaction on mortality and re-fracture after zoledronic acid in hospitalized elderly osteoporotic fracture patients
- PMID: 37247006
- DOI: 10.1007/s00198-023-06803-w
The impact of acute-phase reaction on mortality and re-fracture after zoledronic acid in hospitalized elderly osteoporotic fracture patients
Abstract
This study involving 674 elderly osteoporotic fracture (OPF) patients undergoing orthopedic surgery investigated the long-term outcomes of acute phase reaction (APR) after initial zoledronic acid (ZOL). Those who had an APR had a 97% higher risk of mortality and a 73% lower rate of re-fracture than patients who did not.
Introduction: Annual infusion of ZOL efficiently decreases the risk of fracture. A temporary APR, consisting of flu-like symptoms, myalgia, and fever, is frequently observed within 3 days after the first dose. This work aimed to identify whether the occurrence of APR after initial ZOL infusion is a reliable indicator of drug efficacy for mortality and re-fracture in elderly OPF patients undergoing orthopedic surgery.
Methods: This retrospectively observed work was constructed on a database prospectively collected from the Osteoporotic Fracture Registry System of a tertiary level A hospital in China. Six hundred seventy-four patients 50 years old or older with newly identified hip/morphological vertebral OPF who received ZOL for the first time after orthopedic surgery were included in the final analysis. APR was identified as a maximum axillary body temperature greater than 37.3 °C for the first 3 days after ZOL infusion. We utilized models of multivariate Cox proportional hazards to compare the risk of all-cause mortality in OPF patients with APR (APR+) and without APR (APR-). Competing risks regression analysis was used to examine the association between the occurrence of APR and re-fracture when mortality was taken into account.
Results: In a fully adjusted Cox proportional hazards model, APR+ patients had a significantly higher risk of death than APR- patients with a hazard ratio [HR] 1.97 (95% CI, 1.09-3.56; P-value = 0.02). Furthermore, in an adjusted competing risk regression analysis, APR+ patients had a significantly reduced risk of re-fracture compared with APR- patients with a sub-distribution HR, 0.27 (95% CI, 0.11-0.70; P-value = 0.007).
Conclusions: Our findings suggested a potential association between the occurrence of APR and increased mortality risk. An initial dose of ZOL following orthopedic surgery was found to be protective against re-fracture in older patients with OPFs.
Keywords: Acute-phase reaction; Elderly people; Mortality; Osteoporosis; Osteoporotic fracture; Re-fracture.
© 2023. International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation.
Similar articles
-
The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial.J Bone Miner Res. 2022 Jan;37(1):21-28. doi: 10.1002/jbmr.4434. Epub 2021 Sep 28. J Bone Miner Res. 2022. PMID: 34585443 Free PMC article. Clinical Trial.
-
ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY.Endocr Pract. 2018 May;24(5):405-410. doi: 10.4158/EP161638.OR. Epub 2018 Mar 2. Endocr Pract. 2018. PMID: 29498910
-
Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion.Osteoporos Int. 2021 Apr;32(4):663-670. doi: 10.1007/s00198-020-05653-0. Epub 2020 Oct 28. Osteoporos Int. 2021. PMID: 33113007
-
Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.Ann Intern Med. 2019 Jul 2;171(1):37-50. doi: 10.7326/M19-0533. Epub 2019 Apr 23. Ann Intern Med. 2019. PMID: 31009947
-
Once-yearly zoledronic acid in hip fracture prevention.Clin Interv Aging. 2009;4:153-64. doi: 10.2147/cia.s5065. Epub 2009 May 14. Clin Interv Aging. 2009. PMID: 19503777 Free PMC article. Review.
Cited by
-
Correlation between diabetes mellitus and refracture risk in patients with osteoporotic fractures: a retrospective cohort study.Aging Clin Exp Res. 2025 Mar 13;37(1):85. doi: 10.1007/s40520-024-02917-1. Aging Clin Exp Res. 2025. PMID: 40074983 Free PMC article.
-
Mortality, bone density and grip strength: lessons from the past and hope for the future?Rheumatol Adv Pract. 2024 Mar 28;8(2):rkae046. doi: 10.1093/rap/rkae046. eCollection 2024. Rheumatol Adv Pract. 2024. PMID: 38690291 Free PMC article.
-
Change in body temperature, not acute-phase reaction, predict anti-Osteoporosis efficacy after the first administration of Zoledronic acid: a prospective observational cohort study.BMC Musculoskelet Disord. 2024 Sep 2;25(1):694. doi: 10.1186/s12891-024-07781-8. BMC Musculoskelet Disord. 2024. PMID: 39223504 Free PMC article.
-
Persistent Flu-Like Symptoms in a Patient With Glaucoma and Osteoporosis.Fed Pract. 2024 May;41(5):159-162. doi: 10.12788/fp.0477. Epub 2024 May 15. Fed Pract. 2024. PMID: 39398966 Free PMC article. No abstract available.
-
Effect of denosumab combination with proximal femoral nail antirotation surgery in elderly patients with intertrochanteric femoral fractures: A comparative study.Bone Rep. 2025 Jul 28;26:101860. doi: 10.1016/j.bonr.2025.101860. eCollection 2025 Sep. Bone Rep. 2025. PMID: 40777861 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous